Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates
Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates
复制标题
硫化铜纳米板选择性去势抵抗性前列腺癌光热消融
DOI：
10.1016/j.urology.2018.11.020
复制
发表时间：
2019-03-01
期刊：
影响因子：
2.1
通讯作者：
Hu, Xiao-yong
中科院分区：
文献类型：
--
作者：
Chen, Jun;Wang, Zhao-jie;Hu, Xiao-yong
目的探讨去势抵抗性前列腺癌的新疗法，提高患者的生活质量，延长患者的生命。材料与方法合成、形态分析、物相分析、光谱分析、光热转换测试参考我们以前的文章。然后进行了近红外光驱动硫化铜（CuS）纳米片抑制前列腺癌细胞生长的体内和体外实验。采用透射电镜、mCherry-LC 3合胞病毒标记、吖啶橙子染色、自噬蛋白等方法检测CuS纳米片诱导的自噬，并采用氯喹抑制自噬过程。在980 nm近红外光驱动下，CuS纳米片在体内外均能抑制前列腺癌细胞的生长，同时引发前列腺癌细胞的自噬和细胞保护作用。结论CuS纳米片是一种值得推荐的去势抵抗性前列腺癌光热治疗剂。自噬抑制提高了CuS纳米片的光热效率，这表明在晚期前列腺癌的治疗中具有良好的应用前景。(C)2018爱思唯尔公司
OBJECTIVE To explore new therapies for castration-resistant prostate cancer to improve patients' quality of life and extend life.MATERIALS AND METHODS The synthesis, morphology analysis, phase analysis, spectral analysis, and photothermal conversion test were referenced to our previous articles. Then near-infrared light-driven copper sulfide (CuS) nanoplates to inhibit the growth of prostate cancer cells in vivo and in vitro was carried out. Transmission electron microscope, mCherry-LC3 syncytial virus labeling, acridine orange staining, and autophagy protein were used to detect the autophagy caused by CuS nanoplates and chloroquine was used to inhibit the process of autophagy.RESULTS The CuS nanoplates prepared in this study feature low cytotoxicity, simple preparation, and high photothermal conversion efficiency. Driven by 980 nm near-infrared light, CuS nanoplates could inhibit the growth of prostate cancer cells in vivo and in vitro, while triggering the autophagy and cytoprotection of prostate cancer cells.CONCLUSION CuS nanoplates are a kind of commendable photothermal therapy agent in castration-resistant prostate cancer treating. Autophagy inhibition enhances the photothermal efficiency of CuS nanoplates, which indicates favorable application prospects in the treatment of advanced prostate cancer. (C) 2018 Elsevier Inc.